Total Payments
$39,787
2024 Payments
$22,593
Companies
38
Transactions
674
Medicare Patients
2,176
Medicare Billing
$341,288
Payment Breakdown by Category
Other$23,647 (59.4%)
Food & Beverage$12,282 (30.9%)
Travel$3,767 (9.5%)
Education$90.96 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,940 | 8 | 52.6% |
| Food and Beverage | $12,282 | 651 | 30.9% |
| Travel and Lodging | $3,767 | 12 | 9.5% |
| Debt forgiveness | $2,707 | 1 | 6.8% |
| Education | $90.96 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | $17,810 | 39 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $7,237 | 19 | $0 (2018) |
| Olympus America Inc. | $2,707 | 1 | $0 (2024) |
| ABBVIE INC. | $2,673 | 140 | $0 (2024) |
| PFIZER INC. | $2,349 | 42 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,152 | 140 | $0 (2024) |
| Gilead Sciences, Inc. | $896.62 | 38 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $798.84 | 84 | $0 (2024) |
| Ardelyx, Inc. | $677.20 | 33 | $0 (2024) |
| Janssen Biotech, Inc. | $491.58 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,593 | 159 | Phathom Pharmaceuticals, Inc. ($17,810) |
| 2023 | $869.76 | 59 | AbbVie Inc. ($324.52) |
| 2022 | $1,551 | 78 | ABBVIE INC. ($535.51) |
| 2021 | $1,491 | 97 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($403.33) |
| 2020 | $1,118 | 70 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($624.84) |
| 2019 | $2,853 | 82 | PFIZER INC. ($1,862) |
| 2018 | $8,261 | 69 | Synergy Pharmaceuticals Inc ($7,190) |
| 2017 | $1,049 | 60 | AbbVie, Inc. ($461.98) |
All Payment Transactions
674 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $1.78 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $33.99 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: LIVER DISEASE | ||||||
| 11/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $2.43 | General |
| Category: Immunology | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $4.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $12.39 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $1.74 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/11/2024 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | Cash or cash equivalent | $33.66 | General |
| Category: Antibiotic | ||||||
| 11/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.49 | General |
| 11/07/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: LIVER DISEASE | ||||||
| 11/01/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $32.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/29/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: LIVER DISEASE | ||||||
| 10/25/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 724 | 9,707 | $412,808 | $173,660 |
| 2022 | 10 | 596 | 778 | $133,611 | $68,816 |
| 2021 | 9 | 533 | 659 | $128,557 | $64,301 |
| 2020 | 10 | 323 | 423 | $78,783 | $34,511 |
Total Patients
2,176
Total Services
11,567
Medicare Billing
$341,288
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 22 | 8,804 | $211,173 | $82,664 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 154 | 263 | $54,504 | $27,553 | 50.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 153 | 163 | $34,263 | $17,741 | 51.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 99 | 152 | $24,249 | $15,153 | 62.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 92 | 92 | $24,699 | $12,208 | 49.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 52 | 52 | $29,256 | $4,220 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 25 | $7,273 | $3,422 | 47.0% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 18 | 18 | $5,649 | $2,878 | 50.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 21 | 22 | $10,538 | $2,510 | 23.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 22 | $2,442 | $1,458 | 59.7% |
| 44361 | Biopsy of small bowel (except ileum) using an endoscope | Facility | 2023 | 14 | 14 | $3,507 | $1,192 | 34.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 28 | $2,445 | $1,158 | 47.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 13 | $1,912 | $1,018 | 53.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 25 | 39 | $898.60 | $486.30 | 54.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 123 | 206 | $42,691 | $21,961 | 51.4% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 112 | 115 | $17,895 | $9,687 | 54.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $16,377 | $8,552 | 52.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 50 | $14,546 | $7,627 | 52.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 68 | 99 | $10,988 | $5,965 | 54.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 102 | 156 | $9,409 | $5,062 | 53.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 48 | 49 | $10,694 | $4,186 | 39.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $5,319 | $2,883 | 54.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $3,486 | $1,699 | 48.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 15 | $2,206 | $1,195 | 54.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 140 | 210 | $39,583 | $23,244 | 58.7% |
About Dr. Dennis Riff, M.D
Dr. Dennis Riff, M.D is a Specialist healthcare provider based in Anaheim, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922004662.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dennis Riff, M.D has received a total of $39,787 in payments from pharmaceutical and medical device companies, with $22,593 received in 2024. These payments were reported across 674 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($20,940).
As a Medicare-enrolled provider, Riff has provided services to 2,176 Medicare beneficiaries, totaling 11,567 services with total Medicare billing of $341,288. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Anaheim, CA
- Active Since 06/27/2005
- Last Updated 01/14/2013
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1922004662
Products in Payments
- VOQUEZNA (Drug) $17,810
- Trulance (Drug) $7,237
- EVIS X1 VIDEO SYSTEM CENTER (Device) $2,707
- XIFAXAN (Drug) $1,700
- PREVNAR - 13 (Biological) $1,411
- IBSRELA (Drug) $677.20
- XELJANZ (Drug) $558.69
- SKYRIZI (Biological) $549.54
- Humira (Biological) $495.99
- RINVOQ (Biological) $457.73
- STELARA (Biological) $363.13
- MAVYRET (Drug) $359.23
- ENTYVIO (Biological) $321.29
- Entyvio (Biological) $316.61
- LINZESS (Drug) $285.03
- TRULANCE (Drug) $268.53
- VIBERZI (Drug) $207.88
- HUMIRA (Biological) $207.73
- OCALIVA (Drug) $186.98
- DUPIXENT (Biological) $156.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Anaheim
Dr. Veena Charu, M.d, M.D
Specialist — Payments: $454,847
Specialist $454,847
Dr. Peter Greaney, M.d, M.D
Specialist — Payments: $92,427
Specialist $92,427
Dr. Cheryl Effron, M.d, M.D
Specialist — Payments: $51,484
Specialist $51,484
Mr. Ravi Makam, M.d, M.D
Specialist — Payments: $17,663
Specialist $17,663
Dr. Ajit Maniam, M.d, M.D
Specialist — Payments: $10,658
Specialist $10,658
Dr. Mahaveer Khemka, M.d, M.D
Specialist — Payments: $7,829
Specialist $7,829